Activating mutations in the human KRAS proto-oncogene are acquired during the earliest stages of colorectal cancer development. If mutant KRAS is to be used as a target for therapy in colorectal cancer, tumor growth should depend on its continued presence. Here, we report that stable knockdown of Kras D12 in murine C26 colorectal cancer cells by RNA interference resulted in loss of transformed properties in vitro. The incidence of subcutaneous tumor formation was reduced by 60% and the lag time was increased sevenfold. Kras 
Activating mutations in the human KRAS proto-oncogene are acquired during the earliest stages of colorectal cancer development. If mutant KRAS is to be used as a target for therapy in colorectal cancer, tumor growth should depend on its continued presence. Here, we report that stable knockdown of Kras D12 in murine C26 colorectal cancer cells by RNA interference resulted in loss of transformed properties in vitro. The incidence of subcutaneous tumor formation was reduced by 60% and the lag time was increased sevenfold. Kras D12 -knockdown tumors grew noninvasively and did not cause morbidity. Remarkably, some of the Kras D12 -knockdown tumors regressed spontaneously, which rendered these mice resistant to parental C26 tumor growth. In immune-deficient hosts, the incidence of tumor formation by Kras D12 -knockdown cells was 100%. None of these tumors regressed spontaneously. We conclude that the reduced incidence of tumor formation by Kras
D12
-knockdown cells is due to tumor cell clearance by the host immune system, but not to an intrinsic inability of these cells to grow out as tumors. Interestingly, Kras D12 knockdown resulted in increased production of interleukin 18 , an immune-stimulatory cytokine that has been implicated in limiting colorectal tumor formation. Thus, mutant Kras D12 suppresses Il-18 production in colorectal tumor cells, which may contribute to evasion of the local immune system during tumor development. Keywords: Ras; interleukin-18; colorectal; immuneevasion; malignancy C26 is an aggressive murine colorectal cancer (CRC) cell line that is widely used for studying CRC growth and metastasis formation. The cell line was originally established from an N-nitroso-N-methylurea (NMU)-induced colorectal carcinoma in BALB/c mice . The KRAS mutation status of many human but not murine CRC cell lines is known. Therefore, we analysed the expression and activity of the three Ras isoforms (H-, K-and Nras) in C26 cells. Hras was not expressed in C26 cells, nor in any of the other human and mouse CRC cell lines analysed. Nras was highly expressed but was not active, and Kras was expressed and constitutively active ( Figure 1a ). We next analysed the C26 Kras gene for activating mutations by RT-PCR and sequence analysis. Whereas codons 13 and 61 showed the wild-type Kras sequence, codon 12 contained a point mutation (GGT>GAT) that results in a G12D amino-acid substitution (Figure 1b ). Alkylating N-nitroso compounds primarily cause G>A point mutations (Zarbl et al., 1985; Brown et al., 1990) . Since activating mutations in Kras contribute to tumor initiation, it seems likely that NMU-induced mutational activation of the Kras gene has been a major causative event during development of the original C26 tumor. G12D is also the most frequently found activating KRAS mutation in human CRC (Andreyev et al., 1998 (Andreyev et al., , 2001 Samowitz et al., 2000) .
To test the contribution of mutant Kras D12 to the transformed and tumorigenic properties of C26 cells, we targeted the Kras D12 allele by RNA interference using a lentiviral vector. We isolated a set of cell lines in which Kras, but not Nras, was stably suppressed (C26-KrasKD). As a control, we established cell lines using lentiviruses that were produced using the empty lentiviral pLL3.7 vector (C26-pLL) (Figure 1c ). C26 cells have a spindle-shaped morphology, characteristic for many transformed cells (Figure 1d ). Knockdown of Kras D12 resulted in loss of the spindle shape and cells appeared flattened and enlarged when compared to parental control cells or to cells transduced with control lentivirus (Figure 1d ). In the set of stable cell lines that were isolated we noted that the morphological reversion strictly correlated with successful Kras knockdown. The in vitro proliferation rate of C26-KrasKD cells was approximately fourfold lower than that of the C26-pLL control cells (Figure 1e) . Analysis of the cell cycle profile showed that Kras D12 knockdown prolonged G1 relative to the S and G2/M phases of the cell cycle (Figure 1f ). Taken together, the results show that Kras D12 knockdown produced a dramatic reversion of the transformed phenotype in these aggressively growing CRC cells in vitro.
Next, we analysed the effect of Kras D12 knockdown on the tumorigenic potential of C26 cells in vivo. To this end, we injected C26-pLL and C26-KrasKD cells subcutaneously into the flanks of syngenic BALB/c mice. C26-pLL control cells rapidly produced visible tumors with a lag time of about 6-7 days. Within 21 days, the tumors had reached a volume of more than 1000 mm 3 with necrosis of the overlying skin and signs of local inflammation. Over time, the health of the mice deteriorated and eventually they had to be killed within Exponentially growing C26 cells were serumstarved overnight and were lysed. The expression and activity of Hras, Nras and Kras was then assessed by the Ras activity assay and subsequent Western blotting, using isoform-specific antibodies (Santa Cruz Biotechnology, F235, F155 and F234) exactly as described (Kranenburg et al., 2001) . Nras is expressed but inactive. Hras is not expressed. Kras is expressed and constitutively active. (b) Total RNA was isolated from C26 cells using RNAzol B. Total RNA (1 mg) was reverse transcribed with random hexamers to obtain cDNA for PCR with forward (5 0 -atgactgagtataaacttgtg) and reverse (5 0 -tcacataactgtacaccttgtcc) primers, yielding a 541 bp product. DNA was isolated from agarose gels (Zymoclean Gel DNA Recovery Kit; Zymo Research, Orange, CA, USA) and was sequenced using primer 5 0 -gtattatttatggcaaatacac and the Big Dye terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Warrington, UK), according to the manufacturer's instructions. Analysis of the products was performed on an ABI Prism 377 DNA Sequencer (PE Biosystems) and revealed an activating point mutation in codon 12 (GGT>GAT), resulting in a G>D amino-acid substitution. (c) pLentiLox 3.7 (pLL3.7) (kindly provided by Professor Van Parijs (Rubinson et al., 2003) ) was digested with XhoI and HpaI and the annealed oligos 5 0 -GTTGGAGCTGATGGCGTAG-ttcaagaga-CTACGCCATCAGCTCCAAC-ttttttc-3 0 and 5 0 -tcgagaaaaaa-GTTGGAGCTGATGGCGTAG-tctcttgaa-CTACGCCATCAGCTCCAACa-3 0 were ligated into pLL3.7 to yield a Kras D12 -directed shRNA-producing vector. The 19 nt Kras D12 target sequences are indicated in capitals in the oligonucleotide sequence; the G-A mutation that generates the Gly-Asp substitution in the 12th amino acid of Kras is underlined. Lentiviruses were produced as described (Carlotti et al., 2004) . Exponentially growing C26 cells were transduced either by control lentivirus or by lentivirus targeting Kras D12 using plasmids encoding the lentiviral gag and pol elements (pMDLgpRRE), the rev protein (pRSV-Rev) and the viral envelope 4 cells/9.6 cm 2 density in six-well plates, in medium containing 5% fetal calf serum. Cells were trypsinized and counted in a blinded manner 2, 4 and 6 days after plating. Results shown are from two independent experiments, performed in triplicate. (f) Exponentially growing C26-pLL and C26-KrasKD cells were labeled with BrdU (50 mM) for 10 min and were subsequently processed for FACScan analysis using FITC-labeled anti-BrdU (Boehringer, Mannheim) and propidium iodide. Fluorescence was measured on a FACSCalibur (Becton Dickinson) and the data were analysed using CellQuest software (Becton Dickinson) Kras D12 knockdown affects tumor malignancy and clearance N Smakman et al 24 days following tumor cell injection. In contrast, 60% of mice (15 of 25) that were injected with C26-KrasKD cells failed to develop macroscopic tumors throughout the course of the experiment, which was ended 100 days after tumor cell injection (Table 1) . The remaining 40% of the mice (10/25) did develop tumors, but the mean lag time was extended to 44.4 days ( Table 1) . In contrast to the aggressively growing C26-pLL tumors, the tumors formed by C26-KrasKD cells grew slowly and indolently over time with the overlying skin remaining intact. Despite the fact that C26-KrasKD tumors grew to far larger volumes than C26-pLL control tumors, the mice remained in excellent condition and their health status remained unaffected (Figure 2a , Table 1 ). On cross-sectioning and microscopic examination of hematoxylin and eosin (H&E)-stained tissue sections, C26-pLL tumors showed massive epidermal invasion, whereas the skin overlying C26-KrasKD tumors remained intact and was not invaded (Figure 2b , upper panel, Table 1 ). Towards the center of C26-pLL tumors, large necrotic areas were observed. In contrast, C26-KrasKD tumor tissue was healthy throughout the entire tumor (Figure 2b , lower panel). C26-pLL tumors are characterized as poorly differentiated carcinomas with no signs of tubule formation or mucus production (Figure 2b ). We noted that Kras knockdown had no apparent effect on the histological differentiation grade (Figure 2b , lower panel).
The effect of RAS deletion on the differentiation state, invasiveness, immunogenicity and morbidity of experimental tumors has so far not been investigated. It has previously been reported that deletion of the KRAS gene or mRNA from human tumor cells completely abolished tumor growth (Shirasawa et al., 1993; Brummelkamp et al., 2002) . This is in apparent contrast to our results showing delayed nonmalignant tumor growth of Kras-suppressed C26 cells. Our results are supported by another study showing that loss of NRAS from human HT1080 fibrosarcoma cells or deletion of KRAS from human DLD-1 colorectal carcinoma cells does not abrogate their tumorigenic potential in immune-deficient mice (Plattner et al., 1996) . How may these discrepancies be reconciled? First, given the nonidentical genetic background of the different cell lines, they may differ in their dependency on endogenous mutant KRAS/Kras. A second explanation could be that tumor growth may have been missed in some of these studies due to termination of the experiments prior to a prolonged lag time.
C26 cells are poorly immunogenic and invariably produce tumors when injected into syngenic BALB/c mice without eliciting a detectable host CTL response (Fearon et al., 1988 (Fearon et al., , 1990 During the course of the experiments three out of 10 C26-KrasKD tumors underwent spontaneous regression after having reached a volume of approximately 400 mm 3 (Table 1) . We reasoned that, if tumor regression was due to an antitumor immune response, the mice may have become immunized against the parental C26 cells. Indeed, we found that the C26-KrasKD 'regressor' mice failed to develop tumors following subcutaneous injection of wild-type C26 cells, while control mice developed large subcutaneous tumors within 15 days (Figure 3a) . Furthermore, depletion of CD8 þ T cells from the regressor mice by repeated injections of anti-CD8 antibody allowed subcutaneous C26 tumor growth following reinjection of tumor cells (Figure 3b ). Although the number of mice in these experiments (n ¼ 3) is too low to draw firm conclusions, the results suggested that the failure of Kras-knockdown cells to efficiently develop tumors could be due, at least in part, to tumor cell clearance by the host immune system.
To test this hypothesis, we injected C26-pLL control cells and C26-KrasKD cells into wild-type and immunedeficient BALB/c mice. C26 control cells formed aggressively growing tumors in 100% of the wild-type and in 100% of the immune-deficient mice with a similar mean lag time of 6.4 and 6.5 days, respectively (Table 1) . This result is consistent with the notion that the parental C26 cells are poorly immunogenic. In both groups of mice, tumor growth had a strong adverse effect on animal health. In contrast to C26-pLL cells, C26-KrasKD cells formed tumors in only 40% of immunecompetent mice, but the incidence in immune-deficient mice was 100% (Table 1) . Furthermore, the lag time of 33.8 days in immune-deficient mice was significantly (Po0.05) shorter than the lag time in immune-competent mice (44.4 days). Partial clearance of the injected C26-KrasKD cells by immune-competent hosts may explain this difference. The slower kinetics with which Kras-suppressed tumors grow out allows more time for ) were injected subcutaneously into immune-competent male BALB/c mice and into athymic immune-deficient male BALB/cAnNCrl-NuBR mice, aged 10 weeks. Tumor growth was assessed thrice weekly until the end of the experiment on day 100 postinjection and the incidence of tumor formation was calculated. The lag time was defined as the time (in days) from the injection until the first signs of macroscopic tumor growth were detected. Regression of established macroscopic tumors was seen in three out of 10 mice. Host morbidity was classified 'Yes' when the health status of the host was compromised as described in Figure 2a . Dermal invasion was analysed on H&E-stained tissue sections. These experiments were performed in accordance with the guidelines of the Animal Experimental Committee, University Medical Center Utrecht, The Netherlands (Campbell et al., 2000) . We conclude that the reduced incidence of tumor formation as a result of Kras D12 knockdown is most likely due to tumor cell clearance by the host immune system and not to an intrinsic inability of these cells to grow out as tumors.
To gain more insight into a possible role for Kras in modulating tumor immunity, we performed a comparative cDNA microarray analysis of the gene expression profiles of parental C26 and Kras D12 -knockdown cells. cDNA preparations of both cell types were labeled with either Cy-3 or Cy-5 and were competitively hybridized on 20 K Agilent Mouse Development Chips. Technical variation was compensated for by performing dye swaps. We found that one of the most strongly upregulated genes (11.7-fold) following Kras knockdown was the gene encoding . This result was confirmed by RT-PCR analysis of Il-18 mRNA levels (Figure 4a) . Furthermore, ELISA analysis of Il-18 levels in the conditioned media of both cell types indicated that Kras D12 knockdown resulted in a drastic increase in Il-18 secretion (Figure 4b ). (a) The regressor mice described above (n ¼ 3) and two control mice were challenged with 10 6 parental C26 cells by subcutaneous injection. Tumor growth was then followed over time by standard caliper measurements 6, 9, 12 and 15 days post injection. After 15 days, the control mice had developed large subcutaneous tumors. The regressor mice did not develop tumors. (b) The regressor mice received intraperitoneal injections of anti-CD8 antibody (clone 2.43; 100 mg) on days À7, À3 and 4 h prior to injection of 10 6 wt C26 tumor cells on day 0. The mice received two additional doses anti-CD8 antibody (100 mg) on days 3 and 7 after tumor cell injection. Tumor growth was measured by standard caliper measurements. These experiments were performed in accordance with the guidelines of the Animal Experimental Committee, University Medical Center Utrecht, The Netherlands Kras D12 knockdown affects tumor malignancy and clearance N Smakman et al Il-18 is produced and released by activated macrophages, Kupffer cells, dendritic cells, Langerhans cells and B cells (Pages et al., 1999 (Pages et al., , 2000 . Importantly, it is also produced by epithelial cells of the gastrointestinal tract, the skin and the airway, where it has been implicated in the host immune defense against tumor development (Pages et al., 1999 (Pages et al., , 2000 . In line with this, Il-18 mRNA and protein are strongly reduced during colorectal tumor formation (Pages et al., 1999 (Pages et al., , 2000 . Interestingly, C26 tumor growth in the liver can be strongly suppressed by Il-18-producing hepatocytes, which was associated with increased cytolytic activity of splenic CTLs towards C26 cells (Leng et al., 2003) . This demonstrates the dramatic impact of local Il-18 production on C26 tumor development.
Our results indicate that endogenous mutant Kras, although acquired at the initial stage of C26 tumor development, remains essential for the malignant properties of this highly aggressive CRC cell line, but not for tumor growth per se. Furthermore, the Kras oncogene controls initiation and maintenance of tumor growth by evasion of the host immune system. The strong suppression of Il-18 by mutant Kras in epithelial tumor cells may contribute to immune evasion. Figure 4 Kras D12 suppresses Il-18. (a) Total RNA was isolated (Trizol) and 10 mg aliquots were used for reverse transcription. PCR analysis (30 cycles) was performed using primer pairs designed to amplify mouse IL-18 (forward: 5 0 -actgtacaaccgcagtaatacg, reverse: 5 0 -agtgaacattacagatttatccc) and 18S rRNA (forward: 5 0 -agttggtg gagcgatttgtc, reverse: 5 0 -tattgctcaatctcgggtgg) at 941C (30s), 531C (30 s) and 721C (1min). (b) C26-pLL and C26-KrasKD cells were grown at 10 6 cells/200 ml complete DMEM for either 24 h or 48 h. The medium was harvested and Il-18 levels were measured using the Il-18 enzyme-linked immunosorbent assay (ELISA) kit (MBL, Naka-ku Nagoya, Japan). The cells were harvested and counted. The bar diagram shows the production of Il-18 per 10 6 cells after 24 and 48 h. The asterisk indicates statistical significance (Po0.05) Kras D12 knockdown affects tumor malignancy and clearance N Smakman et al
